|Articles|March 10, 2023
- Pharmaceutical Executive: March 2023
- Volume 43
- Issue 3
Pharmaceutical Executive, March 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive March 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 3 years ago
Navigating Disruption in the Metapharma Eraalmost 3 years ago
Biopharma M&A: Year in Review, Ripples Aheadalmost 3 years ago
Balancing Pharma Hiring Practices in Good Times and Badalmost 3 years ago
Being KOL-Centric: More Meaningful Expert Engagementalmost 3 years ago
A New Era of Influence: Embracing the KOL-DOL Dynamic in Healthcarealmost 3 years ago
Food for Thought: Make Room for Multiple Opinionsalmost 3 years ago
The Pivot to Digitalalmost 3 years ago
More than Ever, Data Will Dictate Future Fortunesalmost 3 years ago
Generative AI’s Breakthrough Potential in Pharma Marketingalmost 3 years ago
The Challenge of Taking on Falsified Medicines in EuropeNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Brent Saunders: Eyeing New Horizons
2
TrumpRX Has a Blind Spot and It Can Redefine Patient Access
3
Lilly’s Retatrutide Displays Positive Topline Results in Successful Phase III Trial
4
FDA Approves Amgen's Uplizna for Generalized Myasthenia Gravis With Positive AChR or MuSK Antibodies
5
